U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07153770) titled 'Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer' on Aug. 26.
Brief Summary: This study aim to evaluate the efficacy and safety of Bozitinib combined with chemotherapy as radical treatment for stage IIA-IIIC MET-altered non-small cell lung cancer
Study Start Date: Sept. 20
Study Type: INTERVENTIONAL
Condition:
NSCLC
MET Exon 14 Mutation
MET Activating Mutation
Intervention:
DRUG: Bozitinib
Participants will receive bozitinib in combination with standard platinum-based doublet chemotherapy for 8 weeks. Following investigator-assessed operability, surgical resec...